Pridopidine is primarily investigated for its potential therapeutic effects in neurodegenerative disorders, particularly Huntington's disease. It acts as a sigma-1 receptor agonist, which is believed to enhance cellular mechanisms that protect neurons and improve motor function. In clinical trials, pridopidine has shown promise in alleviating motor symptoms associated with Huntington's disease, such as involuntary movements and muscle control issues. Additionally, it is being explored for its neuroprotective properties, which could slow disease progression by promoting neuronal survival and reducing cellular stress. Beyond Huntington's disease, pridopidine is also being studied for its potential benefits in other neurological conditions, including amyotrophic lateral sclerosis (ALS) and Parkinson's disease, due to its ability to modulate pathways involved in neurodegeneration.